SVRA - Savara Inc.
| Previous Close | 1.1100 |
| Open | 1.0800 |
| Bid | 1.0800 x 1800 |
| Ask | 1.1600 x 2900 |
| Day's Range | 1.0650 - 1.1500 |
| 52 Week Range | 0.6900 - 11.9600 |
| Volume | 176,506 |
| Avg. Volume | 497,479 |
| Market Cap | 46M |
| Beta (3Y Monthly) | 0.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4970 |
| Earnings Date | Nov 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.44 |
- Business Wire
Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors
Savara Inc. (SVRA), an orphan lung disease company, today announced the appointment of Dr. An van Es-Johansson, M.D. to its Board of Directors, effective immediately. Dr. van Es-Johansson has extensive experience in the development of FDA- and EMA-approved orphan products and has held global leadership roles across multiple disciplines of the life sciences industry, including clinical development, regulatory, and medical affairs.
- GuruFocus.com
2 Falling Knives for Investors to Consider
These companies have a low financial burden Continue reading...
- Business Wire
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Savara Inc. (SVRA), an orphan lung disease company, today announced that on November 26, 2019, the independent members of the Company's Board of Directors granted Badrul Chowdhury, M.D., Ph.D., the Company's new Chief Medical Officer, an option to purchase 300,000 shares of the Company's common stock with an exercise price of $1.01 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date of November 26, 2019. The option vests as to 1/16th of the number of shares subject to the option each quarter with vesting commencing on November 15, 2019, subject to continued employment on each such vesting date, and the option has a ten-year term.
- Business Wire
Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Savara Inc. , an orphan lung disease company, will be presenting at the Evercore ISI HealthCONx conference on Wednesday, December 4, 2019 at 2:20 PM ET / 11:20 AM PT at the Four Seasons Hotel in Boston.
- Business Wire
Savara Appoints Badrul Chowdhury, M.D., Ph.D as Chief Medical Officer
Savara Inc. (SVRA), an orphan lung disease company, today announced the appointment of Badrul Chowdhury, M.D., Ph.D., to the newly created position of Chief Medical Officer (CMO), effective immediately. Dr. Chowdhury will be Savara’s senior physician overseeing the medical and regulatory strategy of the Company’s investigational programs from late-stage development through to approval.
- ACCESSWIRE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA
NEW YORK, NY / ACCESSWIRE / November 15, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. ("Savara" or the "Company") (NASDAQ:SVRA). Such investors ...
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. – SVRA
Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (SVRA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Savara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Business Wire
Savara to Present at the Stifel 2019 Healthcare Conference
Savara Inc. , an orphan lung disease company, will be presenting at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:00 PM ET / 12:00 PM PT at the Lotte New York Palace Hotel.
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA
Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (SVRA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Savara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Business Wire
Savara Reports Third Quarter 2019 Financial Results and Provides Business Update
Company in Discussions with Regulatory Agencies on Best Path Forward for the Molgradex Autoimmune Pulmonary Alveolar Proteinosis Program
- Business Wire
Savara to Report Third Quarter 2019 Financial Results and Provide Business Update
Savara Inc. , an orphan lung disease company, today announced that the Company will report third quarter 2019 financial results and provide a business update on Thursday, November 7, 2019.
- Simply Wall St.
Have Insiders Been Buying Savara Inc. (NASDAQ:SVRA) Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- ACCESSWIRE
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Savara Inc. (SVRA)
NEW YORK, NY / ACCESSWIRE / October 3, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Savara Inc. ("Savara" or "the Company") ...
- Business Wire
Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program
Savara Inc. (SVRA), an orphan lung disease company, today announced the response from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the Molgradex development program for autoimmune pulmonary alveolar proteinosis (aPAP). In the written response received by Savara on October 1, the FDA indicated that the data provided in the briefing package do not provide sufficient evidence of efficacy and safety and did not recommend that the Company submit a Biologics License Application (BLA). The Company is working to determine the next steps for the Molgradex development program.
- Insider Monkey
Mangrove Partners’ Return, AUM, and Holdings
Back in 2010, Nathaniel August, an activist investor, decided it was time to launch his own hedge fund, and he named it Mangrove Partners after a tree species that has the ability to survive extreme weather conditions such as storms and hurricanes. The idea behind this name was to symbolically present hedge fund that is […]
- Simply Wall St.
Some Savara (NASDAQ:SVRA) Shareholders Have Taken A Painful 79% Share Price Drop
As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...
